Clinical Trial Update: Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of a 4-month regimen combining OPC-167832, delamanid, and bedaquiline for drug-susceptible pulmonary tuberculos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Tuberculosis

Drugs mentioned

• Delamanid (delamanid)
• OPC-167832 (OPC-167832)
• bedaquiline (bedaquiline)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Pulmonary TB | Phase 2 | Status: COMPLETED